| Item type |
文献 / Documents(1) |
| 公開日 |
2024-10-18 |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| item_1722929371688 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1210/jendso/bvae034 |
|
|
言語 |
ja |
|
|
関連名称 |
10.1210/jendso/bvae034 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Nasal Glucagon Reverses Insulin-induced Hypoglycemia With Less Rebound Hyperglycemia : Pooled Analysis of Clinical Trials |
|
言語 |
en |
| 著者 |
Seaquist, Elizabeth
Giménez, Marga
Yan, Yu
松久, 宗英
Kao, Christi Yuting
Wadwa, R. Paul
Nagai, Yukiko
Khunti, Kamlesh
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background: Rebound hyperglycemia may occur following glucagon treatment for severe hypoglycemia. We assessed rebound hyperglycemia occurrence after nasal glucagon (NG) or injectable glucagon (IG) administration in patients with type 1 diabetes (T1D) and type 2 diabetes (T2D).
Methods: This was a pooled analysis of 3 multicenter, randomized, open-label studies (NCT03339453, NCT03421379, NCT01994746) in patients ≥18 years with T1D or T2D with induced hypoglycemia. Proportions of patients achieving treatment success [blood glucose (BG) increase to ≥70 mg/dL or increase of ≥20 mg/dL from nadir within 15 and 30 minutes]; BG ≥70 mg/dL within 15 minutes; in-range BG (70-180 mg/dL) 1 to 2 and 1 to 4 hours postdose; and BG >180 mg/dL 1 to 2 and 1 to 4 hours postdose were compared. Incremental area under curve (iAUC) of BG >180 mg/dL and area under curve (AUC) of observed BG values postdose were analyzed. Safety was assessed in all studies.
Results: Higher proportions of patients had in-range BG with NG vs IG (1-2 hours: P = .0047; 1-4 hours: P = .0034). Lower proportions of patients had at least 1 BG value >180 mg/dL with NG vs IG (1-2 hours: P = .0034; 1-4 hours: P = .0068). iAUC and AUC were lower with NG vs IG (P = .025 and P < .0001). As expected, similar proportions of patients receiving NG or IG achieved treatment success at 15 and 30 minutes (97-100%). Most patients had BG ≥70 mg/dL within 15 minutes (93-96%). The safety profile was consistent with previous studies.
Conclusion: This study demonstrated lower rebound hyperglycemia risk after NG treatment compared with IG. |
|
言語 |
en |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
hypoglycemia |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
nasal glucagon |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
rebound hyperglycemia |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
type 1 and 2 diabetes |
| bibliographic_information |
en : Journal of the Endocrine Society
巻 8,
号 4,
p. bvae034,
発行日 2024-02-26
|
| 収録物ID |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
24721972 |
| 出版者 |
|
|
出版者 |
Endocrine Society |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Oxford University Press |
|
言語 |
en |
| item_10001_rights_15 |
|
|
言語 |
en |
|
権利情報 |
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence, which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| item_1723180141928 |
|
|
識別子 |
409203 |
|
識別子タイプ |
URI |
| 言語 |
|
|
言語 |
eng |
jes_8_4_bvae034.pdf (421 KB)
.png)
